TTrialPathMatch Me to Trials
← Back to study

Eligibility check

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Step 1 of 5

Where are you located?

We confirm your state so we only show studies you can actually reach.

Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.